📣 VC round data is live. Check it out!

Waldencast Valuation Multiples

Discover Waldencast's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Ontex Group, Warpaint London, LifeMD, Midsona and more.

Waldencast Overview

About Waldencast

Waldencast PLC is a beauty and wellness operating platform. The company is organized into two reportable segments namely Obagi Skincare and Milk Makeup. The company generates the majority of its revenue from the Obagi Medical segment. The Obagi Medical segment is engaged in developing, marketing, and selling skin health products. The Milk Makeup segment includes developing, marketing, and selling cosmetics, skincare, and other beauty products. Geographically the company generates the majority of its revenue from North America region.


Founded

2020

HQ

United States

Employees

335

Financials (LTM)

Revenue: $283M
EBITDA: $24M

EV

$358M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Waldencast Financials

Waldencast reported last 12-month revenue of $283M and EBITDA of $24M.

In the same LTM period, Waldencast generated $203M in gross profit, $24M in EBITDA, and had net loss of ($178M).

Revenue (LTM)


Waldencast P&L

In the most recent fiscal year, Waldencast reported revenue of $272M and EBITDA of $21M.

Waldencast is unprofitable as of last fiscal year, with gross margin of 67%, EBITDA margin of 8%, and net margin of (84%).

See analyst estimates for Waldencast
LTMLast FY202320242025202620272028
Revenue$283M$272M$218M$274M$272M
Gross Profit$203M$183M$142M$192M$183M
Gross Margin72%67%65%70%67%
EBITDA$24M$21M($34M)$29M($178M)
EBITDA Margin9%8%(15%)10%(65%)
EBIT Margin(45%)(24%)(38%)(20%)(24%)
Net Profit($178M)($230M)($90M)($42M)($230M)
Net Margin(63%)(84%)(41%)(15%)(84%)
Net Debt-$106M---

Financial data powered by Morningstar, Inc.

Waldencast Stock Performance

Waldencast has current market cap of $240M, and enterprise value of $358M.

Market Cap Evolution


Waldencast's stock price is $1.87.

Waldencast share price increased by 50.8% in the last 30 days, and decreased by 23.7% in the last year.

Waldencast has an EPS (earnings per share) of $-1.79.

See more trading valuation data for Waldencast
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$358M$240M2.2%50.8%96.9%-23.7%$-1.79

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Waldencast Valuation Multiples

Waldencast trades at 1.3x EV/Revenue multiple, and 14.8x EV/EBITDA.

See NTM and 2027E valuation multiples for Waldencast

EV / Revenue (LTM)


Waldencast Financial Valuation Multiples

As of June 3, 2026, Waldencast has market cap of $240M and EV of $358M.

Waldencast has a P/E ratio of (1.4x).

LTMLast FY202320242025202620272028
EV/Revenue1.3x1.3x1.6x1.3x1.3x
EV/EBITDA14.8x17.3x(10.7x)12.5x(2.0x)
EV/EBIT(2.8x)(5.5x)(4.4x)(6.7x)(5.5x)
EV/Gross Profit1.8x2.0x2.5x1.9x2.0x
P/E(1.4x)(1.0x)(2.7x)(5.7x)(1.0x)
EV/FCF-(21.7x)(11.3x)(30.3x)(21.7x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Waldencast Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Waldencast Margins & Growth Rates

Waldencast grew revenue by 9% and EBITDA by 41% in the last fiscal year.

In the most recent fiscal year, Waldencast reported gross margin of 67%, EBITDA margin of 8%, and net margin of (84%).

See estimated margins and future growth rates for Waldencast

Waldencast Margins

Last FY202420252026202720282029
Gross Margin67%70%67%74%
EBITDA Margin8%10%(65%)10%
EBIT Margin(24%)(20%)(24%)(19%)
Net Margin(84%)(15%)(84%)(27%)
FCF Margin(6%)(4%)(6%)-

Waldencast Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth9%26%(1%)9%
Gross Profit Growth20%35%(5%)20%
EBITDA Growth41%(185%)(722%)(116%)
EBIT Growth(13%)(35%)21%(13%)
Net Profit Growth(65%)(53%)441%(65%)
FCF Growth-(63%)39%-

Data powered by FactSet, Inc. and Morningstar, Inc.

Waldencast Operational KPIs

Waldencast's revenue per employee in the last FY averaged $0.8M, while opex per employee averaged $0.7M for the same period.

Waldencast's Rule of 40 is 19% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Waldencast's Rule of X is 33% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Waldencast
LTMLast FY202320242025202620272028
Rule of 4016%19%---
Bessemer Rule of X28%33%---
Revenue per Employee-$0.8M---
Opex per Employee-$0.7M---
R&D Expenses to Revenue2%2%1%-2%
Opex to Revenue-91%102%90%91%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Waldencast Competitors

Waldencast competitors include Ontex Group, Warpaint London, LifeMD, Midsona, Nu Skin, MTI Ltd., Leifheit, Acme United, Weight Watchers and Lavipharm.

Most Waldencast public comparables operate across Health & Beauty.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Ontex Group0.4x0.4x4.2x4.3x
Warpaint London1.6x1.5x7.5x7.4x
LifeMD1.0x1.0x13.0x13.8x
Midsona0.6x0.6x8.1x7.8x
Nu Skin0.2x0.2x1.3x-
MTI Ltd.0.6x0.6x2.9x3.7x
Leifheit0.6x0.6x6.9x7.0x
Acme United1.0x1.0x9.8x-

This data is available for Pro users. Sign up to see all Waldencast competitors and their valuation data.

Start Free Trial

Acquisitions by Waldencast

Waldencast has acquired 1 company to date.

Last acquisition by Waldencast was on July 23rd 2025. Waldencast acquired Novaestiq for $3M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Waldencast

Novaestiq
Description
Novaestiq is a Tel Aviv-based developer of aesthetic and medical dermatology products targeting skin rejuvenation and condition treatment. Its portfolio features advanced formulations for anti-aging, pigmentation correction, and acne management using proprietary delivery systems. The company partners with clinics in Europe and the Middle East to distribute professional-grade devices and topicals.
HQ CountryUnited States
HQ City
Dallas, TX
Deal Date23 Jul 2025
Valuation$3M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Waldencast acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by Waldencast

Waldencast has invested in 5 companies to date.

Latest investment by Waldencast was on April 21st 2022. Waldencast invested in Revea in their $6M Seed round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Waldencast

Revea
Sallve
Manual
C16 Biosciences
Description
Revea is a US-based precision skincare company offering personalized formulations based on genetic testing and skin analysis. Customers receive custom-blended serums targeting concerns like aging and hyperpigmentation through at-home kits shipped nationwide. The service partners with dermatologists for clinical validation.
Sallve is a São Paulo-based direct-to-consumer skincare brand launched in 2018, offering affordable, dermatologist-developed products including antioxidant moisturizers, hyaluronic acid serums, retinol treatments, and broad-spectrum sunscreens. Backed by digital entrepreneurs and beauty influencers like Julia Petit, it emphasizes transparent formulations free of irritants, rigorous clinical testing, and e-commerce accessibility to challenge traditional cosmetics pricing in Brazil. The brand has grown rapidly through social media engagement and partnerships with local manufacturers for clean, high-efficacy ingredients.
London-headquartered Manual operates a direct-to-consumer telemedicine platform specializing in men's health diagnostics and treatments. The service dispatches at-home blood test kits analyzing testosterone levels, cholesterol, thyroid function, and vitamin deficiencies alongside consultations with General Medical Council-registered doctors. Prescription medications for erectile dysfunction, hair loss, weight loss, and skin conditions arrive via next-day delivery with subscription options. Unlimited chat support enables ongoing monitoring and adjustments for proactive wellbeing management. Manual launched in 2018 serving UK residents exclusively.
C16 Biosciences is a Berkeley, California-headquartered biotech company producing precision-fermented alternatives to palm oil using yeast strains. Its Palmless platform yields Torula oil for cosmetics and food with omega-6 fatty acids proven in clinical trials for skin barrier repair. Founded in 2021, the firm partners with L'Oréal and Unilever for sustainable ingredients replacing tropical oils.
HQ CountryUnited StatesBrazilUnited KingdomUnited States
HQ City
San Francisco, CA
São Paulo
London
New York City, NY
Deal Date21 Apr 202226 Apr 202130 Mar 20212 Mar 2020
RoundSeedSeries BSeries ASeries A
Raised$6M$20M$30M$20M
InvestorsAlpha Edison; GISEV Family Office; Kathaka; Precursor Ventures; Ulta Beauty; V3 ventures; Verlinvest; Waldencast; West Quad VenturesAstella; Atlantico; Bossa Invest; Canary; Endeavor Catalyst; Kaszek; Quartz; Red Swan Ventures; WaldencastAcurio Ventures; Cherry Ventures; Felix Capital; FJ Labs; GISEV Family Office; Kuvi Capital; Sonoma Brands Capital; Synetro Group; WaldencastAME Cloud Ventures; Breakthrough Energy Ventures; DCVC; Erik Peterson; Friále; Future Tech Lab; Liquid 2 Ventures; Pioneer Fund; Sound Ventures; Waldencast; Y Combinator
Valuationundisclosedundisclosedundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Waldencast investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Waldencast

When was Waldencast founded?Waldencast was founded in 2020.
Where is Waldencast headquartered?Waldencast is headquartered in United States.
How many employees does Waldencast have?As of today, Waldencast has over 335 employees.
Who is the CEO of Waldencast?Waldencast's CEO is Michel Brousset.
Is Waldencast publicly listed?Yes, Waldencast is a public company listed on Nasdaq.
What is the stock symbol of Waldencast?Waldencast trades under WALD ticker.
When did Waldencast go public?Waldencast went public in 2021.
Who are competitors of Waldencast?Waldencast main competitors include Ontex Group, Warpaint London, LifeMD, Midsona, Nu Skin, MTI Ltd., Leifheit, Acme United, Weight Watchers, Lavipharm.
What is the current market cap of Waldencast?Waldencast's current market cap is $240M.
What is the current revenue of Waldencast?Waldencast's last 12 months revenue is $283M.
What is the current revenue growth of Waldencast?Waldencast revenue growth (NTM/LTM) is 8%.
What is the current EV/Revenue multiple of Waldencast?Current revenue multiple of Waldencast is 1.3x.
What is the current EBITDA of Waldencast?Waldencast's last 12 months EBITDA is $24M.
What is Waldencast's EBITDA margin?Waldencast's last 12 months EBITDA margin is 9%.
What is the current EV/EBITDA multiple of Waldencast?Current EBITDA multiple of Waldencast is 14.8x.
How many companies Waldencast has acquired to date?As of June 2026, Waldencast has acquired 1 company.
What was the largest acquisition by Waldencast?$3M acquisition of Novaestiq on 23rd July 2025 was the largest M&A Waldencast has done to date.
What companies Waldencast acquired?Waldencast acquired Novaestiq.
In how many companies Waldencast has invested to date?As of June 2026, Waldencast has invested in 5 companies.
What was the last Waldencast investment?On 21st April 2022 Waldencast invested in Revea, participating in a $6M Seed round, alongside Alpha Edison, GISEV Family Office, Kathaka, Precursor Ventures, Ulta Beauty, V3 ventures, Verlinvest, and West Quad Ventures.
In what companies Waldencast invested in?Waldencast invested in Manual, Sallve, C16 Biosciences, The Nue Co., and Revea.

See public comps similar to Waldencast

Lists including Waldencast

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial